CLIA Lab Director and Personnel Rules: What Changed for Genetic Testing Labs
Short answer: The CLIA final rule CMS-3326-F tightened who may direct and staff high-complexity laboratories. Most provisions took effect January 27, 2024, and the personnel provisions took effect December 28, 2024. Grandfathering protects only people already in role, with continuous employment after that date. Genetic labs should audit personnel files against 42 CFR Part 493.
Why CLIA personnel rules matter for genetic testing labs
Every molecular and genetic testing lab that reports patient results in the United States operates under the Clinical Laboratory Improvement Amendments. High-complexity testing, which covers most sequencing, array and complex molecular workflows, carries the strictest personnel standards. When those standards change, the lab director, technical supervisor and testing-personnel files are what surveyors, accreditors and payers examine first. A staffing gap that surfaces during an inspection can also surface during a payer audit of the lab's billing eligibility.
CMS published the final rule, CMS-3326-F, on December 28, 2023, as announced in its memo QSO-24-03-CLIA. According to the Federal Register notice summarizing the rule's information-collection requirements, it was published at 88 FR 89976 and covered histocompatibility, personnel and fee provisions. The personnel standards had not been comprehensively updated for decades, according to the Baker Donelson summary of the rule.
The effective dates labs should keep straight
The CMS memo states that most provisions took effect January 27, 2024. It lists a defined set of exceptions that took effect December 28, 2024, including the amended definitions in 42 CFR 493.2 and the personnel sections running from 493.1359 and 493.1405 through 493.1491. Secondary summaries are not always consistent on these dates, and at least one describes the rule as effective in January 2025. Compliance teams should rely on the CMS memo and the regulation text rather than trade-press shorthand.
The memo does not list the fee sections, 493.557 through 493.680, as exceptions to the general January 27, 2024 date, so they appear to have taken effect at that earlier date. The memo does not state this in so many words, which is another reason to confirm the date against the Federal Register text before relying on it in a policy document.
What changed in lab director qualifications
For high-complexity laboratory directors who hold an MD, DO or DPM, the Baker Donelson summary reports two additions: at least 20 continuing-education hours in laboratory practice covering director responsibilities, and two years of experience directing or supervising high-complexity testing. The summary also reports that the equivalency allowance for equivalent board certifications was removed.
For doctoral-degree directors, CMS now requires an earned doctoral degree, per the CMS memo. Baker Donelson reports that a doctorate is defined as a post-baccalaureate degree with at least three years of graduate-level study including research related to laboratory testing, and that a Doctor of Veterinary Medicine is excluded. A degree outside the listed fields may qualify when paired with 16 semester hours of doctoral-level coursework in biology, chemistry, medical technology, clinical laboratory science or medical laboratory science, or an approved thesis or research project in those fields. The term physical science was removed from the list of permitted fields.
The Association for Diagnostics and Laboratory Medicine (ADLM) reports that nursing degrees are not treated as biological science degrees and do not qualify for the director role, that the Doctor of Clinical Laboratory Science degree qualifies for the high-complexity director role, and that a proposed master's-equivalency pathway for that role was dropped from the final rule. The CMS memo adds that a proposed nursing-degree qualification for high-complexity testing personnel was removed.
Degree equivalency, onsite visits and grandfathering
Baker Donelson reports a degree-equivalency pathway: 120 semester hours from an accredited institution can count as a bachelor's degree when they include either 48 semester hours of medical laboratory science or technology courses, or 48 semester hours of science courses with specified chemistry and biology minimums. The master's equivalent adds 16 semester hours of graduate coursework or a combination with an approved thesis or research project.
The same summary reports that directors of high- and moderate-complexity labs must be onsite at least once every six months, with at least a four-month interval between visits. For genetic labs that run multi-site or remote-supervised models, that is a documentation item worth checking against the regulation text and against the proposals discussed in our coverage of the CLIA proposed rule on virtual access and personnel.
Grandfathering is the provision most likely to be misapplied. Per Baker Donelson, grandfathering for lab director, technical supervisor, consultant and testing-personnel changes applies only to individuals in the role as of December 28, 2024, and only so long as employment is continuous after that date. A grandfathered director who leaves and later returns, or a technical supervisor promoted from another site after that date, may not retain the protection. Labs should document each person's start date and continuity of service.
Fee changes in the same rule
The CMS memo describes new fees for follow-up surveys, specialty surveys, substantiated complaint surveys, desk review of unsuccessful proficiency testing, and revised or replacement certificates. It also describes an 18 percent across-the-board increase to existing fees, a $25 increase in the Certificate of Waiver fee to cover obligations to FDA, and fee increases every two years based on a CPI-U inflation adjustment and, if applicable, an additional across-the-board increase.
ADLM also reports that sanctions for non-compliant Certificate of Waiver laboratories now include civil monetary penalties, directed plans of correction and onsite state monitoring, where previously sanctions were limited to revocation, suspension or limitation of the certificate.
The recordkeeping burden behind the rule
In a July 2, 2026 Federal Register notice, HHS sought comment on extending the CLIA recordkeeping information collection, CMS-R-26 under OMB control number 0938-0612. The notice cites the 2023 final rule as a basis for the updated policies and estimates 49,626 respondents, 88,259,802 total annual responses and 14,514,802 total annual hours. The notice itself does not mention genetic testing, but it shows the scale of documentation the CLIA program expects from laboratories.
A practical audit checklist
Start with the director file: confirm the degree type, board certification or doctoral pathway, documented training and experience, and the continuing-education record. Next, match each technical supervisor, technical consultant and testing-personnel file to the regulation sections that took effect December 28, 2024, and flag anyone relying on grandfathering. Then verify that onsite-visit logs exist, that competency assessment schedules are documented, and that your fee and certificate renewals reflect the 2024 changes. Finally, track the broader regulatory direction, including the CMS CLIA regulations request for information and the Enhancing CLIA Act proposal for lab-developed tests, since further personnel changes would build on this baseline.
Labs that are sorting out ordering workflows and documentation can also review how ScreenMyGene supports decision-making on the ScreenMyGene homepage.
Frequently asked questions
When did the CLIA personnel changes take effect?
According to CMS memo QSO-24-03-CLIA, most provisions took effect January 27, 2024, while the listed personnel and definition provisions took effect December 28, 2024. Labs should confirm each section against the Federal Register text before updating policies, because secondary summaries sometimes state different dates.
Does grandfathering protect every existing lab director?
Not automatically. Baker Donelson reports that grandfathering covers only individuals in their role as of December 28, 2024, and only while employment remains continuous after that date. Labs should document start dates and continuity of service for each grandfathered person.
Can a nursing degree qualify someone as a lab director?
ADLM reports that nursing degrees are not treated as biological science degrees and do not qualify for the laboratory director role. The CMS memo also states that a proposed nursing-degree qualification for high-complexity testing personnel was removed from the final rule.
What fee changes came with the rule?
The CMS memo describes new fees for follow-up, specialty and complaint surveys, desk review of unsuccessful proficiency testing, and revised certificates, plus an 18 percent increase to existing fees, a $25 Certificate of Waiver increase, and CPI-U adjustments every two years.
Where should a lab verify requirements?
Use the current text of 42 CFR Part 493 and the Federal Register publication of CMS-3326-F, along with guidance from your accreditor or state agency. Trade summaries, including those cited here, are secondary sources and may not reflect later amendments.
This article is for educational purposes only and does not constitute legal, regulatory, compliance or medical advice. Requirements vary by laboratory type, state and accreditor. Consult qualified counsel or your accrediting body before making compliance decisions.
Sources: CMS memo QSO-24-03-CLIA (Dec 28, 2023); Baker Donelson, "CMS Enacts New CLIA Regulations Effective January 2025"; ADLM Lab Advocate, "CMS Releases New Updates to CLIA" (2024); HHS Federal Register notice, 91 FR 126, July 2, 2026 (CMS-R-26, FR Doc. 2026-13465).